

# Appendix W: Additional health economic results

## Contents

<b>A.2 Guideline economic analysis on parent training for the management of behaviour that challenges in children and young people with a learning disability.....</b>	<b>2</b>
<b>A.3 Guideline economic analysis on sleep interventions .....</b>	<b>3</b>
<b>A.4 Guideline economic analysis on antipsychotics for the management of behaviour that challenges in children and young people with a learning disability.....</b>	<b>5</b>

## Abbreviations


ICER	incremental cost-effectiveness ratio
N/A	not applicable
NICE	National Institute for Health and Care Excellence
QALY	quality adjusted life year

## A.1 Guideline economic analysis on parent training for the management of behaviour that challenges in children and young people with a learning disability

**Table W.1. Deterministic results of economic analysis of parent training for the management of behaviour that challenges in children and young people with a learning disability: mean costs and QALYs for 100 families of children and young people with a learning disability receiving treatment**

Intervention	Mean total cost	Mean total QALYs	ICER versus waitlist
Group parent training	£36,230	79.20	£28,067/QALY
Waitlist	£0	77.91	N/A
Incremental	£36,230	1.33	

**Figure W.1. Cost effectiveness plane showing incremental costs and QALYs of parent training versus waitlist – mean probabilistic results**



- The straight line shows the lower NICE cost-effectiveness threshold of £20,000 per QALY; the dotted line shows the upper NICE cost-effectiveness threshold of £30,000 per QALY.
- The circle represents parent training, while waitlist is placed at the origin.

## A.2 Guideline economic analysis on sleep interventions


**Table W.2. Deterministic results of economic analysis of psychosocial, pharmacological and combined interventions for the management of sleep problems in children and young people with a learning disability: mean costs and QALYs per child or young person receiving treatment**

Intervention	Probability of non-improvement in sleep problems under waitlist					
	0.900			0.925		
	Total cost	Total QALYs	ICER (£/QALY)	Total cost	Total QALYs	ICER (£/QALY)
Waitlist	0	0.4520		0	0.4504	
Psychosocial intervention	£447	0.4669	ext dominance	£447	0.4628	Ext dominance
Melatonin – tablets	£412	0.4779	£15,872	£412	0.4749	£16,830
Melatonin – oral solution	£558	0.4779	dominated	£558	0.4749	Dominated
Melatonin – oral suspension	£757	0.4779	dominated	£757	0.4749	Dominated
Combination – tablets	£858	0.4966	£23,846	£858	0.4955	£21,644
Combination – oral solution	£1,005	0.4966	dominated	£1,005	0.4955	Dominated
Combination – oral suspension	£1,203	0.4966	dominated	£1,203	0.4955	Dominated

Intervention	Probability of non-improvement in sleep problems under waitlist					
	0.950			0.975		
	Total cost	Total QALYs	ICER	Total cost	Total QALYs	ICER
Waitlist	0	0.4489		0	0.4473	
Psychosocial intervention	£447	0.4580	ext dominance	£447	0.4524	Ext dominance
Melatonin – tablets	£412	0.4714	£18,285	£412	0.4673	Ext dominance
Melatonin – oral solution	£558	0.4714	dominated	£558	0.4673	Dominated
Melatonin – oral suspension	£757	0.4714	dominated	£757	0.4673	Dominated
Combination – tablets	£858	0.4942	£19,559	£858	0.4927	£18,911
Combination – oral solution	£1,005	0.4942	dominated	£1,005	0.4927	Dominated
Combination – oral suspension	£1,203	0.4942	dominated	£1,203	0.4927	Dominated

**Figure W.2. Cost effectiveness plane showing incremental costs and QALYs of sleep interventions versus waitlist – mean probabilistic results**




- The straight line shows the lower NICE cost-effectiveness threshold of £20,000 per QALY; the dotted line shows the upper NICE cost-effectiveness threshold of £30,000 per QALY.
- Waitlist is placed at the origin.

### A.3 Guideline economic analysis on antipsychotics for the management of behaviour that challenges in children and young people with a learning disability

**Table W.3. Deterministic results of economic analysis of antipsychotics for the management of behaviour that challenges in children and young people with a learning disability: mean costs and QALYs for 100 children and young people with a learning disability receiving treatment**

Intervention	Mean total cost	Mean total QALYs	Incremental analysis
Risperidone – orodispersible tablets	£268	0.448	Dominated
Risperidone – oral solution	£98	0.448	Dominated
Risperidone – tablets	£17	0.448	£1,420/QALY
Aripiprazole	£490	0.443	Dominated
Waitlist	£0	0.437	

**Figure W.3. Cost effectiveness plane showing incremental costs and QALYs of antipsychotics versus placebo – mean probabilistic results**



- The straight line shows the lower NICE cost-effectiveness threshold of £20,000 per QALY; the dotted line shows the upper NICE cost-effectiveness threshold of £30,000 per QALY.
- Waitlist is placed at the origin.